Navigation Links
PPD to Acquire InnoPharm Ltd.
Date:2/6/2008

s. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the closing and its contribution to PPD, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: risks associated with acquisitions and investments, such as integration and impairments; international business risks; the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; continued success in sales growth; loss of large contracts; increased cancellation rates; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PP
'/>"/>

SOURCE PPD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Neogen Acquires Kane Enterprises
4. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
7. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
8. NSF International Acquires David Begg Associates
9. United BioSource Acquires Caro Research, Leader in Simulation Modeling
10. Groupe Novasep to Acquire PharmaChem Technologies (Grand Bahama) Ltd
11. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015   Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... supply industries, today reported financial results for the second ... half of 2015, we remain on track to achieve ... and Chief Executive Officer of the Company. "Since our ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
... Jan. 7 Sangart, Inc., a privately ... and,commercialization of oxygen-therapeutic agents, today announced a ... key leadership positions and,a significant reduction in ... This restructuring reduces the company,s burn rate ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
Cached Biology Technology:Volcano Announces Closing of Axsun Technologies Acquisition 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 3Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... mountains are thinning is not disputed. However, few researchers ... Lawrence Berkeley National Laboratory scientist Surabi Menon set out ... culpritgreenhouse gases, such as carbon dioxidefrom other particles in ... and her collaborators found that airborne black carbon aerosols, ...
... 3, 2010 For Immediate Release A team of ... that act on novel binding sites for an enzyme used ... AIDS. The discovery lays the foundation for the development of ... treat drug-resistant strains of the disease, and slow the evolution ...
Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
... Ultrapure ACS Reagent Grade C 19 H ... Weight: 691.95 PRODUCT SPECIFICATIONS Form: Powder Clarity ... pH 3.0 - Yellow pH ... tracking dye in agarose and acrylamide gel ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... CHEMICONs ELF 97 Cytological Labeling Kit ... facilitate the detection of cellular targets, including ... 97 Cytological Labeling Kit contains the patented ... brightly fluorescent yellow-green precipitate at the site ...
Biology Products: